



LYTGOBI® tablets can provide

The power you want. The care patients need.

- **42% ORR*** (95% CI: 32%, 52%) (N=103)¹
- **9.7 months mDoR** (95% CI: 7.6, 17.1)¹

Take on advanced cholangiocarcinoma (CCA) with LYTGOBI, an approved irreversibly binding *FGFR* inhibitor designed to help you target appropriate patients and offer personalized support along their treatment journey.¹⁻³

INDICATION AND USAGE

LYTGOBI is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (*FGFR2*) gene fusions or other rearrangements.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **Ocular Toxicity:** LYTGOBI can cause Retinal Pigment Epithelial Detachment (RPED), which may cause symptoms such as blurred vision. RPED occurred in 9% of 318 patients who received LYTGOBI across clinical trials.

CI=confidence interval; *FGFR*=fibroblast growth factor receptor; mDoR=median duration of response; ORR=overall response rate.

*Responses were partial in the single-arm, phase 2 FOENIX-CCA2 study (TAS-120-101).¹

Please see Important Safety Information throughout and full Prescribing Information at [LYTGOBI.com/PI](https://www.lytgo.com/PI).



LYTGOBI®
(futibatinib) tablets 4 mg

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Biliary Tract Cancers^{1,4}

For patients with previously treated unresectable or metastatic intrahepatic cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (*FGFR2*) gene fusions or rearrangements if disease progression

NCCN Guidelines® Recommended Option


NCCN CATEGORY
2A*

Futibatinib (LYTGOBI®) is recommended as a National Comprehensive Cancer Network® (NCCN®) subsequent-line systemic therapy option for unresectable or metastatic intrahepatic or extrahepatic cholangiocarcinoma with *FGFR2* fusions or rearrangements if disease progression[†]

Sample[‡] treatment algorithm for subsequent-line use for CCA with *FGFR2* fusions or rearrangements:

Primary Therapy for Unresectable and Metastatic Disease

Durvalumab +
gemcitabine + cisplatin



Subsequent-Line Therapy if Disease Progression

Futibatinib (LYTGOBI)

*NCCN Category 2A recommendation: based upon lower-level evidence, there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.

†Treatment selection depends on clinical factors, including previous treatment regimen/agent, somatic molecular testing results, and extent of liver dysfunction.

‡These treatment algorithms are examples only; other treatment options are recommended in the NCCN Guidelines.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Biliary Tract Cancers V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed April 9, 2025. To view the most recent and complete version of the guideline, go online to [NCCN.org](https://www.nccn.org).

NCCN makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (continued)

- **Ocular Toxicity (continued):** The median time to first onset of RPED was 40 days. RPED led to dose interruption of LYTGOBI in 1.3% of patients, dose reduction in 1.6% of patients, and permanent discontinuation in 0.3% of patients. Perform a comprehensive ophthalmological examination, including optical coherence tomography (OCT) of the macula, prior to initiation of therapy, every 2 months for the first 6 months, and every 3 months thereafter. For onset of visual symptoms, refer patients for ophthalmologic evaluation urgently, with follow-up every 3 weeks until resolution or discontinuation of LYTGOBI. Withhold or reduce the dose of LYTGOBI as recommended. **Dry Eye/Corneal Keratitis:** Among 318 patients who received LYTGOBI across clinical trials, dry eye occurred in 15% of patients. Treat patients with ocular demulcents as needed.

Please see Important Safety Information throughout and full Prescribing Information at [LYTGOBI.com/PI](https://www.lytgo.com/PI).


An approved irreversibly binding *FGFR* inhibitor^{1-3,5}

Designed to covalently bind to *FGFR*^{1-3,5-7}

LYTGOBI tablets, a tyrosine kinase inhibitor, show targeted antitumor activity against *FGFR*-deregulated tumors. LYTGOBI is a unique treatment in that it covalently binds in the *FGFR* kinase domain at sites not targeted by reversible ATP-competitive *FGFR* inhibitors.

- *FGF* signaling via *FGFR*s plays an important role in tumor proliferation and survival¹
- *FGFR2* alterations account for 10%-16% of patients with iCCA, most of which are *FGFR2* fusions⁷

ATP=adenosine triphosphate;
FGF=fibroblast growth factor;
FGFR=fibroblast growth factor receptor;
iCCA=intrahepatic cholangiocarcinoma.



LYTGOBI binds to the *FGFR* in an irreversible manner and exhibits antiproliferative activity against cancer cell lines.^{1,5}



LYTGOBI®
(futibatinib) tablets 4 mg

Efficacy and safety assessed in a phase 2 study^{1,5,8}

FOENIX-CCA2 (TAS-120-101) was a multicenter, open-label, single-arm, phase 2 study in patients with unresectable locally advanced or metastatic intrahepatic CCA harboring an *FGFR2* fusion or rearrangement.

PATIENTS

Key eligibility criteria



- Unresectable or metastatic intrahepatic CCA
- *FGFR2* fusions or other rearrangements
- Measurable disease per RECIST v1.1
- Prior gemcitabine + platinum-based chemotherapy
- Progression after ≥1 systemic therapy
- ECOG PS 0 or 1
- No prior treatment with *FGFR* inhibitor

PATIENT BASELINE CHARACTERISTICS (N=103)



- Median age was 58 years, with a range of 22-79 years
- ECOG PS was Category 0 in 47% of patients and Category 1 in 53%
- 100% of patients had at least 1 prior treatment; 30% had at least 2; and 23% had ≥3
- 78% of patients had fusions, and 22% had rearrangements, as their *FGFR2* aberration*
- 22% of patients ≥65 years
- 56% of patients were female
- Races were: 50% White, 29% Asian, 8% Black or African American, 1% Native Hawaiian or Other Pacific Islander, 13% unknown

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (continued)

- **Hyperphosphatemia and Soft Tissue Mineralization:** LYTGObI can cause hyperphosphatemia leading to soft tissue mineralization, calcinosis, nonuremic calciphylaxis, and vascular calcification. Hyperphosphatemia was reported in 88% of 318 patients treated with LYTGObI across clinical trials with a median time of onset of 5 days (range 3-117). Phosphate binders were received by 77% of patients who received LYTGObI. Monitor for hyperphosphatemia throughout treatment. Initiate a low-phosphate diet and phosphate-lowering therapy when serum phosphate level is ≥5.5 mg/dL; initiate or intensify phosphate-lowering therapy when >7 mg/dL; reduce dose, withhold, or permanently discontinue LYTGObI based on duration and severity of hyperphosphatemia.

Please see Important Safety Information throughout and full Prescribing Information at [LYTGObI.com/PI](https://www.lytgo.com/PI).

TREATMENT



LYTGObI® tablets 20 mg orally once daily, continuously

Treatment was administered until disease progression, drug intolerance, withdrawal of consent, or death.

A maximum of 2 dose reductions (to 16 mg and then to 12 mg) were permitted to manage treatment-emergent ARs.[†]

Note: Prophylactic treatment was not administered for hyperphosphatemia.⁸

ENDPOINTS



Primary (by IRC):

- Overall response rate

Secondary:

- Duration of response
- DCR
- PFS
- OS
- Safety
- Patient-reported outcomes

FOLLOW-UP



Follow-up continued for up to 18 months after enrollment of last patient.

AR=adverse reaction; DCR=disease control rate; ECOG PS=Eastern Cooperative Oncology Group performance status; IRC=independent review committee; OS=overall survival; PFS=progression-free survival; RECIST v1.1=Response Evaluation Criteria for Solid Tumors version 1.1.

*Determined by Foundation Medicine Central (n=68), Foundation Medicine Local reports (n=25), or by local testing (n=10); 2 patients had *FGFR2* mutations in addition to fusions.⁹

[†]Treatment was discontinued if treatment-emergent ARs did not resolve after 2 dose modifications or if the next cycle of treatment was delayed >21 days.⁵




LYTGObI®
(futibatinib) tablets 4 mg

Powered to enable a response¹

42% of patients responded to treatment with LYTGObI® tablets

Primary endpoint: overall response rate (ORR)




The **ORR** for LYTGObI was
42%
(95% CI: 32%, 52%)
• PR: 42%

Durable cholangiocarcinoma treatment results¹

Secondary endpoint: duration of response (DoR)

Median DoR
9.7 Months
(95% CI: 7.6, 17.1)



72% of responders (n=31) had responses that lasted ≥6 months

14% of responders (n=6) had responses that lasted ≥1 year

2.5 months median TTR (range: 0.7-7.4)

PR=partial response; TTR=time to response.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS (continued)

• **Embryo-fetal Toxicity:** Based on findings in an animal study and its mechanism of action, LYTGObI can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise female patients of reproductive potential, and males with female partners of reproductive potential, to use effective contraception during treatment with LYTGObI and for 1 week after the last dose.

ADVERSE REACTIONS

- **Serious adverse reactions** occurred in 39% of patients receiving LYTGObI, and in ≥2% of patients included pyrexia (3.9%), gastrointestinal hemorrhage (3.9%), ascites (2.9%), musculoskeletal pain (2.9%), and bile duct obstruction (2.9%).
- **The most common adverse reactions** (≥20%) were nail toxicity (47%), musculoskeletal pain (43%), constipation (39%), diarrhea (39%), fatigue (37%), dry mouth (35%), alopecia (34%), stomatitis (30%), abdominal pain (30%), dry skin (29%), arthralgia (25%), dysgeusia (25%), dry eye (25%), nausea (24%), decreased appetite (23%), urinary tract infection (23%), palmar-plantar erythrodysesthesia syndrome (21%), and vomiting (20%).



Please see Important Safety Information throughout and full Prescribing Information at [LYTGObI.com/PI](https://www.lytgo.com/PI).



LYTGObI
(futibatinib) tablets 4 mg

An established safety profile with LYTGOBI® tablets¹

ARs (≥15%) in patients receiving LYTGOBI in the FOENIX-CCA2 trial

LYTGOBI (N=103)		
ARs	All grades ^a (%)	Grade 3 (%)
Skin and subcutaneous tissue disorders		
Nail toxicity ^b	47.0	1.9
Alopecia	34.0	0
Dry skin	29.0	0
Palmar-plantar erythrodysesthesia syndrome	21.0	4.9
Gastrointestinal disorders		
Constipation	39.0	0
Diarrhea ^c	39.0	1.0
Dry mouth	35.0	0
Stomatitis ^d	30.0	6.0
Abdominal pain ^e	30.0	2.9
Nausea	24.0	1.9
Vomiting ^f	20.0	1.0

LYTGOBI (N=103)		
ARs	All grades ^a (%)	Grade 3 (%)
General disorders		
Fatigue ^g	37.0	8.0
Metabolism and nutrition disorders		
Decreased appetite	23.0	2.9
Musculoskeletal and connective tissue disorder		
Musculoskeletal pain ^h	43.0	3.9
Arthralgia ⁱ	25.0	0
Eye disorders		
Dry eye ^j	25.0	1.0
Nervous system disorders		
Dysgeusia ^k	25.0	0
Infections		
Urinary tract infection ^l	23.0	2.9
Investigations		
Weight decreased	18.0	3.9

^aGraded per NCI CTCAE 4.03.¹

^bIncludes nail toxicity, nail disorder, nail discoloration, nail dystrophy, nail hypertrophy, nail infection, nail pigmentation, onychalgia, onychoclasia, onycholysis, onychomadesis, onychomycosis, and paronychia.¹

^cIncludes diarrhea, colitis, and gastroenteritis.¹

^dIncludes stomatitis, glossitis, mouth ulceration, mucosal inflammation, pharyngeal inflammation, and tongue ulceration.¹

^eIncludes abdominal pain, abdominal discomfort, abdominal pain upper, gastrointestinal pain, and hepatic pain.¹

^fIncludes vomiting and hematemesis.¹

^gIncludes fatigue and asthenia.¹

^hIncludes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, musculoskeletal stiffness, myalgia, neck pain, non-cardiac chest pain, pain in extremity, and spinal pain.¹

ⁱIncludes arthralgia and arthritis.¹

^jIncludes dry eye, keratitis, lacrimation increased, photokeratitis, punctate keratitis, and ulcerative keratitis.¹

^kIncludes dysgeusia, ageusia, and taste disorder.¹

^lIncludes urinary tract infection, cystitis, and dysuria.¹

- Among the most common (≥15%) ARs experienced by patients taking LYTGOBI in FOENIX-CCA2, no Grade 4 or 5 reactions occurred
- Clinically relevant adverse reactions occurring in ≤15% of patients included retinal pigment epithelial detachment (RPED, 7.8%)

Use of LYTGOBI is also associated with the following serious risks: ocular toxicity, hyperphosphatemia and soft tissue mineralization, and embryo-fetal toxicity.

Please see Important Safety Information throughout and full Prescribing Information at LYTGOBI.com/PI.

An established safety profile (continued)

Select laboratory abnormalities (≥10%) worsening from baseline in patients receiving LYTGOBI in the FOENIX-CCA2 trial

LYTGOBI (N=103)		
Laboratory Abnormality ^a	All grades ^b (%)	Grades 3 or 4 (%)
Hematology		
Decreased hemoglobin	52.0	6.0
Decreased lymphocytes	46.0	10.0
Decreased platelets	42.0	1.0
Decreased leukocytes	33.0	1.1
Decreased neutrophils	31.0	1.6
Chemistry		
Increased phosphate ^c	97.0	39.0
Increased creatinine ^d	58.0	0
Increased glucose	52.0	4.9
Increased calcium	51.0	1.2
Decreased sodium	51.0	15.0
Decreased phosphate	50.0	20.0
Increased alanine aminotransferase	50.0	7.0
Increased alkaline phosphatase	47.0	4.9
Increased aspartate aminotransferase	46.0	13.0
Decreased albumin	31.0	2.4
Increased creatine kinase	31.0	5.0
Increased bilirubin	28.0	0
Decreased glucose	25.0	0
Decreased potassium	22.0	2.1
Increased potassium	16.0	2.0
Coagulation		
Increased activated partial thromboplastin time	36.0	8.0
Increased prothrombin international normalized ratio	25.0	0


^aGraded per NCI CTCAE 4.03.

^bPercentages are based on patients with data at both baseline and at least one post-baseline data value.

^cNCI CTCAE 4.03 does not define grades for increased phosphate. Laboratory value shift table categories were used to assess increased phosphorus levels (Grades ≥3 defined as >7 mg/dL).

^dGraded based on comparison to upper limit of normal.

■ Straightforward, continuous, once-daily oral dosing¹



Starting dosage

LYTGObi® tablets are 4 mg each. The recommended starting dose of LYTGObi is 20 mg (5 tablets). LYTGObi is taken orally once per day. It is taken continuously until disease progression or unacceptable toxicity occurs.

It can be taken with or without food, and patients should take their prescribed dose at the same time each day.

LYTGObi tablets should be swallowed whole. Do not crush, chew, split, or dissolve tablets.

Advise patients to avoid grapefruit products during treatment with LYTGObi.

If a dose is missed for more than 12 hours or if vomiting occurs, resume dosing with the next scheduled dose.

Remember: Day 1 is row 1. Each row of tablets equals one daily dose.

Prior to initiation of therapy, patients are required to undergo a comprehensive ophthalmological examination including optical coherence tomography, every 2 months for the first 6 months, and every 3 months thereafter and urgently at any time for visual symptoms.

IMPORTANT SAFETY INFORMATION

ADVERSE REACTIONS (continued)

- **The most common laboratory abnormalities** ($\geq 20\%$) were increased phosphate (97%), increased creatinine (58%), decreased hemoglobin (52%), increased glucose (52%), increased calcium (51%), decreased sodium (51%), decreased phosphate (50%), increased alanine aminotransferase (50%), increased alkaline phosphatase (47%), decreased lymphocytes (46%), increased aspartate aminotransferase (46%), decreased platelets (42%), increased activated partial thromboplastin time (36%), decreased leukocytes (33%), decreased albumin (31%), decreased neutrophils (31%), increased creatine kinase (31%), increased bilirubin (28%), decreased glucose (25%), increased prothrombin international normalized ratio (25%), and decreased potassium (22%).


Please see Important Safety Information throughout and full Prescribing Information at [LYTGObi.com/PI](https://www.lytgo.com/PI).

■ Alternative DosePaks® available

In the event that dose modifications are required, alternative DosePaks are available to make dosing convenient for patients.


First dose reduction^{1*}

16 mg (four 4-mg tablets) orally once daily.



Second dose reduction^{1*}

12 mg (three 4-mg tablets) orally once daily.



*Permanently discontinue LYTGObi if unable to tolerate 12 mg orally once daily.¹

IMPORTANT SAFETY INFORMATION

DRUG INTERACTIONS

- **Dual P-gp and Strong CYP3A Inhibitors:** Avoid concomitant use of drugs that are dual P-gp and strong CYP3A inhibitors.
- **Dual P-gp and Strong CYP3A Inducers:** Avoid concomitant use of drugs that are dual P-gp and strong CYP3A inducers.



LYTGObi®
(futibatinib) tablets 4 mg

Recommended dosage modifications for adverse reactions¹

HYPERPHOSPHATEMIA

Severity	LYTGOBI® tablets dose modifications
Serum phosphate ≥5.5 - ≤7.0 mg/dL	Continue LYTGOBI at the current dose and initiate phosphate-lowering therapy. Monitor serum phosphate weekly.
Serum phosphate >7.0 - ≤10.0 mg/dL	- Initiate or adjust phosphate-lowering therapy. Monitor serum phosphate weekly and - Reduce LYTGOBI to next lower dose - If the serum phosphate resolves to ≤7.0 mg/dL within 2 weeks after dose reduction, continue at this reduced dose - If serum phosphate is not ≤7.0 mg/dL within 2 weeks, further reduce LYTGOBI to the next lower dose - If serum phosphate is not ≤7.0 mg/dL within 2 weeks after the second dose reduction, withhold LYTGOBI until serum phosphate is ≤7.0 mg/dL and resume at the dose prior to suspending
Serum phosphate >10.0 mg/dL	- Initiate or adjust phosphate-lowering therapy and monitor serum phosphate weekly and - Withhold LYTGOBI until phosphate is ≤7.0 mg/dL and resume LYTGOBI at the next lower dose - Permanently discontinue LYTGOBI if serum phosphate is not ≤7.0 mg/dL within 2 weeks following 2 dose interruptions and reductions

RETINAL PIGMENT EPITHELIAL DETACHMENT (RPED)

LYTGOBI dose modifications

- Continue LYTGOBI at the current dose and continue periodic ophthalmic evaluation:
- If resolving within 14 days, continue LYTGOBI at the current dose
 - If not resolving within 14 days, withhold LYTGOBI until resolving; then resume LYTGOBI at previous or a lower dose

OTHER ADVERSE REACTIONS

LYTGOBI dose modifications

- In the case of Grade 3* adverse reaction, withhold LYTGOBI until toxicity resolves to Grade 1 or baseline, then resume LYTGOBI
 - For hematological toxicities resolving within 1 week, at the dose prior to suspending
 - For other adverse reactions, at the next lower dose
- In the case of Grade 4* adverse reaction, permanently discontinue LYTGOBI

¹² *Severity as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE 4.03).

Taiho Oncology Patient Support™ contributes to the care they need

Taiho Oncology Patient Support™ offers personalized services to help give patients, caregivers, and healthcare professionals access to Taiho Oncology products. This includes insurance coverage determination and help with medication affordability.

For more information, please visit or refer patients to **TaihoPatientSupport.com**.



Meeting the access needs of your patients

Getting patients access to their medicine is an important step. Taiho Oncology Patient Support strives to make this process as simple as possible.

Taiho Oncology Patient Support can assist with:

- Insurance Coverage Support***
 - Benefits investigation, prior authorization assistance, and appeals assistance if needed
 - Coordination of prescriptions with pharmacies
- Personalized Nurse Support†**
 - One-on-one nurse educational support for patients, available via opt-in
- Patient Affordability Assistance**
 - \$0 co-pay program enrollment for eligible commercially insured patients
 - Patient assistance program designed to provide free medication to eligible patients who are uninsured or underinsured
 - Referrals to third-party foundations for co-pay or other assistance based on eligibility and additional criteria
 - Referrals to Medicare Part D Low-Income Subsidy (LIS)/Extra Help Program

A brochure is available to help your patients and their caregivers through treatment with LYTGOBI.

*Visit TaihoPatientSupport.com to see full eligibility criteria.
†If selected on the Patient Enrollment Form, a Nurse Navigator will be assigned to provide telephone support and will address general inquiries about LYTGOBI treatment.

Please see Important Safety Information throughout and full Prescribing Information at [LYTGOBI.com/PI](https://www.taihooncology.com/PI).





LYTGOBI®
(futibatinib) tablets 4mg

LYTGOBI® tablets are indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.¹

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).¹

LYTGOBI can provide

The power you want. The care patients need.

- An approved irreversibly binding *FGFR* inhibitor¹⁻³
 - **42%** overall response rate¹
 - 95% CI: 32%, 52%; N=103
 - **9.7** months median duration of response¹
 - 95% CI: 7.6, 17.1
 - Continuous, once-daily oral dosing¹
 - No Grade 4 or 5 reactions occurred, among the most common (≥15%) ARS^{1*}
 - Use of LYTGOBI is associated with the following serious risks: ocular toxicity, hyperphosphatemia and soft tissue mineralization, and embryo-fetal toxicity¹
 - Serious adverse reactions occurred in 39% of patients receiving LYTGOBI, and in ≥2% of patients included pyrexia (3.9%), gastrointestinal hemorrhage (3.9%), ascites (2.9%), musculoskeletal pain (2.9%), and bile duct obstruction (2.9%)
 - The most common adverse reactions (≥20%) were nail toxicity (47%), musculoskeletal pain (43%), constipation (39%), diarrhea (39%), fatigue (37%), dry mouth (35%), alopecia (34%), stomatitis (30%), abdominal pain (30%), dry skin (29%), arthralgia (25%), dysgeusia (25%), dry eye (25%), nausea (24%), decreased appetite (23%), urinary tract infection (23%), palmar-plantar erythrodysesthesia syndrome (21%), and vomiting (20%)
- *In the FOENIX-CCA2 trial.⁸

IMPORTANT SAFETY INFORMATION

USE IN SPECIFIC POPULATIONS

- **Lactation:** Because of the potential for serious adverse reactions from LYTGOBI in breastfed children, advise women not to breastfeed during treatment and for 1 week after the last dose.
- **Hepatic Impairment:** Patients with hepatic impairment may have the potential for increased adverse reactions compared to patients with normal hepatic function.

References: 1. LYTGOBI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2024. 2. Kalyukina M, Yosaatmadja Y, Middleditch MJ, Patterson AV, Smaill JB, Squire CJ. TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure. *ChemMedChem*. 2019;14(4):494-500. doi:10.1002/cmdc.201800719 3. Sootome H, Fujita H, Ito K, et al. Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. *Cancer Res*. 2020;80(22):4986-4997. doi:10.1158/0008-5472.CAN-19-2568 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Biliary Tract Cancers V.1.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed April 9, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. 5. Bridgewater JA, Meric-Bernstam F, Hollebecque A, et al. Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring *FGFR2* fusions/rearrangements: subgroup analyses of a phase II study (FOENIX-CCA2). Poster presented at: European Society of Medical Oncology Virtual Congress; September 19-21, 2020. 6. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. *Nat Rev Cancer*. 2010;10(2):116-129. doi:10.1038/nrc2780 7. Jain A, Borad MJ, Kelley RK, et al. Cholangiocarcinoma with *FGFR* genetic aberrations: a unique clinical phenotype. *JCO Precis Oncol*. 2018;2:1-12. doi:10.1200/PO.17.00080 8. Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for *FGFR2*-rearranged intrahepatic cholangiocarcinoma. *N Engl J Med*. 2023;388(3):228-239. doi:10.1056/NEJMoa2206834 9. Goyal L, Meric-Bernstam F, Hollebecque A, et al. Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR 1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma with *FGFR2* fusions/rearrangements. Abstract presented at: American Association for Cancer Research Annual Meeting; April 10-15, 2021, and May 17-21, 2021; Philadelphia, PA. Abstract CT010.

Please see Important Safety Information throughout and full Prescribing Information at [LYTGOBI.com/PI](https://www.lytgo.com/PI).



TAIHO ONCOLOGY